Boundless Bio, Inc. Common Stock – NASDAQ:BOLD
Boundless Bio, Inc. Common Stock stock price today
$1.11
-1.43
-56.47%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Boundless Bio, Inc. Common Stock stock price monthly change
-37.50%
month
Boundless Bio, Inc. Common Stock stock price quarterly change
-37.50%
quarter
Boundless Bio, Inc. Common Stock key metrics
Market Cap | 56.64M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -2.39 |
Revenue | N/A |
EBITDA | -58.60M |
Income | -53.14M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBoundless Bio, Inc. Common Stock stock price history
Boundless Bio, Inc. Common Stock stock forecast
Boundless Bio, Inc. Common Stock financial statements
| Jun 2023 | 0 | -12.39M | |
|---|---|---|---|
| Sep 2023 | 0 | -13.17M | |
| Dec 2023 | 0 | -12.14M | |
| Mar 2024 | 0 | -15.43M |
| Dec 2023 | 0 | -12.14M | |
|---|---|---|---|
| Mar 2024 | 0 | -15.43M | |
| Sep 2025 | 0 | -24.12M | |
| Dec 2025 | 0 | -25.68M |
Analysts Price target
Financials & Ratios estimates
| 2019-08-06 | -1.04 | -1.01 |
|---|---|---|
| 2019-11-07 | -1.07 | -1 |
| 2024-05-13 | -0.55 | -12.27 |
| Jun 2023 | 154931000 | 258.79M | 167.04% |
|---|---|---|---|
| Sep 2023 | 143738000 | 259.78M | 180.73% |
| Dec 2023 | 129894000 | 256.97M | 197.84% |
| Mar 2024 | 117077000 | 10.64M | 9.09% |
| Jun 2023 | -10.89M | -68.52M | 99.69M |
|---|---|---|---|
| Sep 2023 | -12.18M | -7.71M | -447K |
| Dec 2023 | -11.68M | 15.81M | -1.38M |
| Mar 2024 | -15.77M | 18.13M | -924K |
Boundless Bio, Inc. Common Stock alternative data
| Apr 2024 | 72 |
|---|---|
| May 2024 | 72 |
| Jun 2024 | 72 |
| Jul 2024 | 72 |
Boundless Bio, Inc. Common Stock other data
-
What's the price of Boundless Bio, Inc. Common Stock stock today?
One share of Boundless Bio, Inc. Common Stock stock can currently be purchased for approximately $1.11.
-
When is Boundless Bio, Inc. Common Stock's next earnings date?
Unfortunately, Boundless Bio, Inc. Common Stock's (BOLD) next earnings date is currently unknown.
-
Does Boundless Bio, Inc. Common Stock pay dividends?
No, Boundless Bio, Inc. Common Stock does not pay dividends.
-
How much money does Boundless Bio, Inc. Common Stock make?
Boundless Bio, Inc. Common Stock has a market capitalization of 56.64M. Boundless Bio, Inc. Common Stock made a loss 49.43M US dollars in net income (profit) last year or -$12.27 on an earnings per share basis.
-
What is Boundless Bio, Inc. Common Stock's stock symbol?
Boundless Bio, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "BOLD".
-
What is Boundless Bio, Inc. Common Stock's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Boundless Bio, Inc. Common Stock?
Shares of Boundless Bio, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Boundless Bio, Inc. Common Stock have?
As Jul 2024, Boundless Bio, Inc. Common Stock employs 72 workers.
-
When Boundless Bio, Inc. Common Stock went public?
Boundless Bio, Inc. Common Stock is publicly traded company for more then 9 years since IPO on 20 Jul 2016.
Boundless Bio, Inc. Common Stock company profile:
Exchange:
NASDAQ
Full time employees:
72
Industry:
Biotechnology
Sector:
Healthcare
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
,
:
ISIN: US10170A1007
:
